Lipocine's PPD drug misses Phase 3 goal, but company cites site data anomalies

Lipocine Inc. reported second quarter 2026 financial results and a pipeline update on August 4, 2026. On April 2, 2026, the company had reported topline results from its Phase 3 placebo-controlled trial of oral LPCN 1154 (oral brexanolone), branded BRLIZIO, for postpartum depression. In the full analysis set, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D total score compared to placebo at hour 60, and the primary endpoint was not met.¹

The company said a post hoc analysis identified problems at one site. Lipocine identified anomalies at one high-enrolling site in the Phase 3 trial that raise substantive questions about the validity of that site's data, and excluding the outlier site, LPCN 1154 produced a rapid, sustained, and clinically meaningful improvement in depression symptoms, according to the company.¹

Lipocine has requested a guidance meeting with the FDA scheduled for the third quarter of 2026, and has initiated a new placebo controlled clinical trial for PPD to complement the existing LPCN 1154 clinical database and further characterize efficacy and safety.¹

In a related program, the same post hoc analysis found that participants with a history of psychiatric conditions showed statistically significant and clinically meaningful reductions in HAM-D scores versus placebo, observed as early as hour 12 and sustained through day 30, and Lipocine plans to submit a Phase 2 protocol to the FDA for LPCN 2201 in major depressive disorder.¹ The company also said it plans to submit a protocol for a Phase 2 study to the FDA and may initiate a study to evaluate LPCN 2203 for essential tremor, citing literature reports of potential efficacy with injectable brexanolone and favorable tolerability observed with oral brexanolone.¹

On the commercial side, Pharmalink received marketing authorization approval for TESTYRA (TLANDO) in the UAE on July 8, 2026.¹

As of June 30, 2026, Lipocine had $23.3 million of unrestricted cash, cash equivalents, and marketable investment securities, compared to $14.9 million at December 31, 2025.¹ The company reported a net loss of $2.6 million, or ($0.32) per diluted share, for the quarter, compared to a net loss of $2.2 million, or ($0.41) per diluted share, a year earlier.¹